Antiviral Therapy
Tripeptide inhibitors staunch the replication of subgenomic hepatitis C RNA
Published in Hepatitis Weekly, February 28th, 2005
"The inadequate efficacy and tolerability of current therapies for the infectious liver disease caused by the hepatitis C virus have warranted significant efforts in the development of new therapeutics. We have previously reported competitive peptide inhibitors of the NS3 serine protease based on the N-terminal cleavage products of peptide substrates," scientists in Canada report.
"A detailed study of the interactions of these substrate-based inhibitors with the different subsites of the serine protease active site led to the discovery of novel residues that increased the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-02-28)
More Articles from Hepatitis Weekly
- Cancer Risk Factors
Overexpressed c-Myc in liver disease patients may cause liver cancer - Diabetes Pathogenesis
Unknown aspects of hepatitis C infection generate insulin resistance - Oncology
Lamivudine prevents hepatitis B reactivation during breast cancer therapy - Zoonosis
Wild boar may spread hepatitis E to deer meat consumed by humans - Adverse Drug Reaction
Hepatitis B vaccine is linked to a dermatological reaction after immunization - Allergy and Immunology
Interferon alpha stimulates autoimmunization in a chronic hepatitis C patient - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
